RAC 2.30% $1.49 race oncology ltd

Ann: Appendix 4E & Annual Report, page-12

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 498 Posts.
    lightbulb Created with Sketch. 616

    Amazing progress on Zantrene development made this FY
    Roadmap lined out for 2023 (and onward)
    Financials are excellent, very disciplined spending.
    $33.5M cash in the bank. Enough for 2-3 years of programs spending even at increased pace.
    Remuneration of Directors on the rise, but overall, remains in line with peers and given the amount of hard work done.
    Chairman's interests aligned with shareholders interest
    Communication to shareholders is, as always, top notch
    Steady shareholder structure, with the exception of a few that we already knew about (BG, MOF).Well absorbed

    Congrats to the whole RAC team, for this year's excellent achievements. I am very much looking forward to FY2023 which in John Cullity's own words will be transformative.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.